23462-75-1

Basic information

• Product Name: 2H-PYRAN-3(4H)-ONE, DIHYDRO-
• Synonyms: DIHYDRO-PYRAN-3-ONE;2H-PYRAN-3(4H)-ONE, DIHYDRO-;5,6-Dihydro-2H-pyran-3(4H)-one;Tetrahydro-2H-pyran-3-one;2H-PYRAN-3(4H)-ONE;tetrahydro-2H-3-pyranone;2H-PYRAN-3(4H)-ONE, DIHYD...;oxan-3-one
• CAS NO: 23462-75-1
• Molecular Formula: C₅H₈O₂
• Molecular Weight: 100.12
• EINECS: 1312995-182-4
• Mol File: 23462-75-1.mol

Chemical Properties

• Boiling Point: 176 °C at 760 mmHg
• Flash Point: 70.4 °C
• Appearance: /
• Density: 1.065 g/cm³
• Vapor Pressure: 1.12mmHg at 25°C
• Refractive Index: 1.44
• Storage Temp.: Inert atmosphere,Store in freezer, under -20°C
• CAS DataBase Reference: 2H-PYRAN-3(4H)-ONE, DIHYDRO-(CAS DataBase Reference)
• NIST Chemistry Reference: 2H-PYRAN-3(4H)-ONE, DIHYDRO-(23462-75-1)
• EPA Substance Registry System: 2H-PYRAN-3(4H)-ONE, DIHYDRO-(23462-75-1)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 23462-75-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
2H-PYRAN-3(4H)-ONE, DIHYDROis used as a chemical reagent for the preparation of tetrahydropyran-2-yl chromans, which are highly selective beta-site amyloid precursor protein cleaving enzyme 1 (BACE) inhibitors. These inhibitors play a significant role in the development of treatments for neurodegenerative diseases such as Alzheimer's.
In the Pharmaceutical Industry:
2H-PYRAN-3(4H)-ONE, DIHYDROis used as a key intermediate in the synthesis of various pharmaceutical compounds. Its unique structure enables the development of novel drugs with potential applications in treating a wide range of medical conditions.

InChI:InChI=1/C5H8O2/c6-5-2-1-3-7-4-5/h1-4H2

Upstream product

• 19752-84-2 Oxan-3-ol 
• 82272-05-7 4-(3,4-dihydro-2H-pyran-5-yl)morpholine 
• 328-50-7 α-ketoglutaric acid 
• 1403495-64-6 3,3-dimethoxytetrahydro-2H-pyran 
• 4469-60-7 dimethyl 2,2-dimethoxypentanedioate 
• 110-87-2 3,4-dihydro-2H-pyran 
• 98166-29-1 2-(3-Propinyloxy)-acetaldehyddiethylacetal 
• 78870-52-7 (1SR,6RS)-3,7-dioxa-bicyclo[4.1.0]heptane 
• 67-56-1 methanol 
• 98166-23-5 2H-pyran-3(6H)-one 
• 73819-79-1 <α-tetrahydropyrannyloxy>-2 tetrahydropyrone-3 (S*, R*) 
• 73819-79-1 <α-tetrahydropyrannyloxy>-2 tetrahydropyrone-3 (S*, S*) 

Downstream Products

• 94394-11-3 5-(5-Benzyl-3,4,5,8-tetrahydro-6-methyl-2H-pyrano<3,2-b>pyridyliden-8)-1,3-dimethylbarbitursaeure 
• 229007-18-5 4-(N-methyl-N-(tetrahydropyran-3-yl)aminomethyl)aniline 
• 848324-33-4 2-amino-4,7-dihydro-5H-thieno[2,3-c]pyran-3-carboxamide 
• 873397-34-3 racemic tetrahydropyran-3-carboxylic acid 
• 1305321-54-3 3-({2-[(benzyloxycarbonyl)amino]-3-phenylpropanoyl}-amino)tetrahydropyran-3-carboxylic acid 
• 1305321-47-4 N-methyl-N-phenyltetrahydropyran-3-carboxamide 
• 1305321-48-5 N-methyl-N-phenyltetrahydropyran-3-thiocarboxamide 
• 1305321-46-3 N-methyl-N-phenyl-5-oxa-1-azaspiro[2.5]oct-1-en-2-amine 
• 1305321-49-6 N-{3-[(N-methyl-N-phenylamino)thioxomethyl]tetrahydropyran-3-yl}benzamide 
• 89464-26-6 tetrahydropyran-3-carbonitrile 
• 1799952-48-9 C₂₂H₂₃F₂N₃O₅ 

Relevant articles and documents

Industrial production method of tetrahydro - 2H - pyran -3 - ketone

To the industrial production method of tetrahydro - 2H - pyran -3 - ketone, starting from 3, 4 - dihydro - 2H - pyran (compound II), a nucleophilic substitution with a bromination reagent generates a compound III. Compound III reacts with morphine to form compound IV. The compound IV is cheap and easily available, is safe and environment-friendly, does not need to use an active agent such as lithium aluminum hydride and NaH, does not need to use peroxide such as hydrogen peroxide, is simple to process after reaction, is easy to purify, and is suitable for industrial production.

Substituted pyridine compound and its method and use thereof

The invention relates to a novel substitutive pyridine compound, and a pharmaceutically acceptable salt and a pharmaceutical preparation of the substitutive pyridine compound for regulating the activity of protein kinases and regulating signal responses between cells or in the cells. Meanwhile, the invention further relates to a pharmaceutical composition containing the compound provided by the invention, and a method for treating high proliferative diseases of mammals, especially human with the pharmaceutical composition.

Method for synthesizing tetrahydro-2H-pyran-3-one and key intermediates thereof

The invention discloses a method for synthesizing tetrahydro-2H-pyran-3-one and key intermediates thereof. The method is characterized by comprising the following steps: a, dissolving a compound I in anhydrous tetrahydrofuran under nitrogen protection, cooling to 0 DEG C, dropwise adding a borane-tetrahydrofuran complex to maintain the temperature of about 0 DEG C, stirring for 2 hours, dropwise adding an aqueous solution of NaOH at room temperature, dropwise adding hydrogen peroxide after dropwise adding completion, controlling the temperature to be 50 DEG C or less, stirring at room temperature for 10 hours after dropwise adding completion so as to obtain a compound II; and b, dissolving the compound II in dichloromethane, adding sodium acetate and TEMPO, adding sodium dichloro isocyanurate in batches at the temperature of below 30 DEG C, maintaining the temperature of 30 DEG C for 2 hours, thereby obtaining a compound III. According to the method disclosed by the invention, 3,4-dihydro-2H-pyran is selected as an initial raw material, the key intermediate tetrahydro-2H-pyran-3-ol of tetrahydro-2H-pyran-3-one is prepared through a hydroboration-oxidation method, and the tetrahydro-2H-pyran-3-ol is oxidized so as to obtain the tetrahydro-2H-pyran-3-one. The synthetic method is simple in operation and readily available in raw materials and can be applicable to large-scale industrial production.

Synthesis of dihydro-2H-pyran-3(4H)-one

A practical synthetic procedure for the synthesis of dihydro-2H-pyran-3(4H) -one is reported. The method commenced from the readily available α-ketoglutaric acid and allowed preparation of the title compound in four steps in 31% overall yield. ARKAT-USA, Inc.

N-methyl-N-phenyl-5-oxa-1-azaspiro[2.5]oct-1-en-2-amine - Synthesis and reactions of a synthon for AN UNKNOWN α-AMINO ACID

The synthesis of the heterospirocyclic amino azirine N-methyl-N-phenyl-5- oxa-1-azaspiro[2.5]oct-1-en-2-amine (6a) was achieved from 3,4-dihydro-2H-pyrane (7) via N-methyl-N-phenyltetrahydropyran-3-thiocarboxamide (11). The reactions of 6a with thiobenzoic acid and Z-Phe-OH, respectively, leading to the corresponding 3-benzoylaminotetrahydropyran-3-thiocarboxamide (13) and the diastereoisomeric dipeptide amides (14), respectively, demonstrate that 6a is a valuable synthon for the hitherto unknown 3-aminotetrahydropyrane-3-carboxylic acid. The structure of 13 was established by X-Ray crystallography. The Japan Institute of Heterocyclic Chemistry.

PYRAZOLOTHIAZOLE COMPOUND

A compound represented by the formula (I) or pharmacologically acceptable salt thereof exhibits an excellent CRF receptor antagonism wherein X is a nitrogen atom or CH; R1 is -A11-A12; A11 is a single bond or a C1-6 alkylene group; A12 is a hydrogen atom, a C1-6 alkyl group or a C3-6 cycloalkyl group, etc.; R2 is -A21-A22; A21 is a single bond or a C1-6 alkylene group; A22 is a hydrogen atom, a C1-6 alkyl group, a C3-6 cycloalkyl group, a non-aromatic heterocyclic group, or a heteroaryl group, etc.; R3 is a C 1-6 alkyl group, a C3-6 cycloalkyl group, a C1-6 alkoxy group, a C3-6 cycloalkoxy C1-6 alkyl group, di-C1-6 alkyl amino group, a halogen atom, a cyano group, a formyl group, or a carboxyl group, etc; R4 is a hydrogen atom or a C1-6 alkoxy group; R5 is a halogen atom, a C1-6 alkyl group, or a C1-6 alkoxy group; R6 is a hydrogen atom, a C1-6 alkyl group, a C1-6 alkoxy group, a C1-6 alkylthio group, or a C1-6 alkyl sulfinyl group etc.; and R7 is a C1-6 alkyl group, a C1-6 alkoxy group, or a C1-6 alkylthio group

PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS

Pyrazine compounds, and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like.

AMINOPYRIDINE AND CARBOXYPYRIDINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS

Pyridine and pyrimidine compounds: or a pharmaceutically acceptable salt thereof, wherein m, n, R1, R2, R3, R4, R5, R6, R7, X1, X2, X3, X4, X5, X6, X7, X8, and Y are as defined in the specification; or a pharmaceutically acceptable salt thereof, wherein ring A, m, n, y, R2, R3, R4, R5, R6, R7, R8, R9, X1, X2, and ring A are as defined in the specification; and or a pharmaceutically acceptable salt thereof, wherein m, n, y, R2, R3, R4, R5, R6, R7, R9, X1, X2, and ring A are as defined in the specification; compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like.

ANTI-HIV COMPOUNDS

Thiazole derivatives represented by Formula (I) are disclosed, where R1, R2, R3, A, X, Y, Z, R6 and R7 are disclosed herein. These thiazole derivatives and pharmaceutical compositions comprising these derivatives are useful in the treatment of HIV mediated diseases and conditions.

3-PHENYLPYRAZOLO[5,1-b]THIAZOLE COMPOUNDS

A compound represented by the following formula (I), or salt thereof exhibits excellent CRF receptor antagonism, and sufficient pharmacological activity, safety and pharmacokinetic properties as a drug. wherein R1 represents the formula -A11-A12; R2 represents tetrahydrofurylmethyl, tetrahydropyranylmethyl or tetrahydropyranyl; A11 represents a single bond, methylene or 1,2-ethylene; A12 represents C1-6 alkyl, C3-6 cycloalkyl or C3-6 cycloalkyl having methyl; R3 represents methoxy, cyano, cyclobutyloxymethyl, methoxymethyl or ethoxymethyl; and R4 represents methoxy or chlorine.